论文部分内容阅读
[目的]评价奥曲肽治疗肝硬化顽固性腹水的疗效和安全性.[方法]计算机检索PubMed、Em-base、Cochrane Library、CBMdisc、CNKI、维普、万方等数据库公开发表的文献,检索年限均从2000年1月至2015年7月.纳入奥曲肽联合内科常规治疗(观察组)与单纯内科常规治疗(对照组)相比较治疗肝硬化顽固性腹水的随机对照试验.由两名评判员对纳入试验独立进行质量评价和资料提取,采用RevMan5.2软件进行Meta分析.[结果]经筛选共纳入10个随机对照试验,合计757例患者.Meta分析结果显示:观察组的总有效率和24 h尿量均高于对照组[OR=2.86,95%CI(1.90,4.31),P<0.05;MD=259.80,95%CI(249.45,270.15),P<0.05],腹围和体质量均低于对照组[MD=-11.72,95%CI(-13.30,-10.14),P<0.05;MD=-4.80,95%CI(-7.02,-2.58),P<0.05].[结论]奥曲肽可显著增加肝硬化顽固性腹水患者的24 h尿量,降低其腹围和体质量,提高其治疗的总有效率.“,”[Objective]To evaluate the efficacy and safety of octreotide in patients with refractory ascites due to cirrhosis.[Methods] The relevant randomized controlled trials were searched throughout PubMed, Embase, Cochrane Library, CBMdisc, CNKI, Chinese VIP database, and WanFang database. All articles were identified by a search from January 2000 to July 2015. Trials comparing the efficacy of octreotide plus routine medical therapy versus routine medical therapy in patients with refractory ascites due to cirrhosis were included. Two investigators independently as-sessed the methodological quality of included trials and performed the data extraction. Meta-analysis was carried out with Review Manager Software 5.2. [Results] Ten eligible trials including 757 patients were included and assessed. According to the results of the meta-analysis, octreotide plus routine medical therapy was remarkably more effective than routine medical therapy in terms of total effective rate [OR=2.86, 95%CI(1.90, 4.31), P<0.05], 24-hour u-rine volume [MD=259.80, 95%CI(249.45, 270.15),P<0.05], abdominal perimeter [MD=-11.72, 95%CI(-13. 30, -10.14),P<0.05], and body weight [MD=-4.80, 95%CI(-7.02, -2.58),P<0.05]. [Conclusions] Oct-reotide can significantly increase the 24-hour urine volume, reduce the abdominal perimeters and body weight, and raise the total effective rate in patients with refractory ascites due to cirrhosis.